|
|
Prepublished online as a Blood First Edition Paper on June 26, 2003; DOI 10.1182/blood-2003-03-0885.
Submitted April 7, 2003
Accepted May 9, 2003
Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease
Robert Kralovics, David W Stockton, and Josef T Prchal*
Department of Research, Basel University Hospital, Basel, Switzerland
Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA; Medicine, Baylor College of Medicine, Houston, TX, USA; Ophtalmology, Baylor College of Medicine, Houston, TX, USA
Medicine, Baylor College of Medicine, Houston, TX, USA
* Corresponding author; email: jprchal{at}bcm.tmc.edu.
Familial clustering of malignancies provides a unique opportunity to identify molecular causes of cancer. Polycythemia vera (PV) is a myeloproliferative disorder due to an unknown somatic stem cell defect that leads to clonal myeloid hyperproliferation. We studied six families with PV. The familial predisposition to PV appears to follow an autosomal dominant inheritance pattern with incomplete penetrance. All examined females informative for a transcriptional clonality assay had clonal hematopoiesis. We excluded linkage between PV and a number of previously proposed candidate disease loci (c-mpl, EPOR, 20q, 13q, 5q, 9p). Therefore, mutations at these loci are unlikely primary causes of familial PV. The finding of erythropoietin-independent erythroid progenitors in normal family members indicated the presence of the PV stem cell clone in their hematopoiesis. This finding, together with clonal hematopoiesis in the affected individuals, supports the hypothesis of multiple genetic defects involved in the early pathogenesis of PV.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Saint-Martin, G. Leroy, F. Delhommeau, G. Panelatti, S. Dupont, C. James, I. Plo, D. Bordessoule, C. Chomienne, A. Delannoy, et al.
Analysis of the Ten-Eleven Translocation 2 (TET2) gene in familial myeloproliferative neoplasms
Blood,
August 20, 2009;
114(8):
1628 - 1632.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Vannucchi, G. Masala, E. Antonioli, M. Chiara Susini, P. Guglielmelli, L. Pieri, L. Maggi, S. Caini, D. Palli, C. Bogani, et al.
Increased Risk of Lymphoid Neoplasms in Patients with Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
Cancer Epidemiol. Biomarkers Prev.,
July 1, 2009;
18(7):
2068 - 2073.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Vannucchi, P. Guglielmelli, and A. Tefferi
Advances in Understanding and Management of Myeloproliferative Neoplasms
CA Cancer J Clin,
May 1, 2009;
59(3):
171 - 191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Spivak
MPDs: it's all in the family
Blood,
September 15, 2008;
112(6):
2173 - 2174.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Levine and D. G. Gilliland
Myeloproliferative disorders
Blood,
September 15, 2008;
112(6):
2190 - 2198.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Landgren, L. R. Goldin, S. Y. Kristinsson, E. A. Helgadottir, J. Samuelsson, and M. Bjorkholm
Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24 577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in Sweden
Blood,
September 15, 2008;
112(6):
2199 - 2204.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Zeoli, P. Dentelli, A. Rosso, G. Togliatto, A. Trombetta, L. Damiano, P. F. di Celle, L. Pegoraro, F. Altruda, and M. F. Brizzi
Interleukin-3 promotes expansion of hemopoietic-derived CD45+ angiogenic cells and their arterial commitment via STAT5 activation
Blood,
July 15, 2008;
112(2):
350 - 361.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Teofili, R. Foa, F. Giona, and L. M. Larocca
Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients?
Haematologica,
February 1, 2008;
93(2):
169 - 172.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. James
The JAK2V617F Mutation in Polycythemia Vera and Other Myeloproliferative Disorders: One Mutation for Three Diseases?
Hematology,
January 1, 2008;
2008(1):
69 - 75.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Rumi, F. Passamonti, M. G. Della Porta, C. Elena, L. Arcaini, L. Vanelli, C. Del Curto, D. Pietra, E. Boveri, C. Pascutto, et al.
Familial Chronic Myeloproliferative Disorders: Clinical Phenotype and Evidence of Disease Anticipation
J. Clin. Oncol.,
December 10, 2007;
25(35):
5630 - 5635.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Yoder, L. E. Mead, D. Prater, T. R. Krier, K. N. Mroueh, F. Li, R. Krasich, C. J. Temm, J. T. Prchal, and D. A. Ingram
Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals
Blood,
March 1, 2007;
109(5):
1801 - 1809.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Skoda
The Genetic Basis of Myeloproliferative Disorders
Hematology,
January 1, 2007;
2007(1):
1 - 10.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Pardanani, R. L. Levine, T. Lasho, Y. Pikman, R. A. Mesa, M. Wadleigh, D. P. Steensma, M. A. Elliott, A. P. Wolanskyj, W. J. Hogan, et al.
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
Blood,
November 15, 2006;
108(10):
3472 - 3476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Xiong, E. Liu, Y. Yan, R. T. Silver, F. Yang, I. H. Chen, Y. Chen, S. Verstovsek, H. Wang, J. Prchal, et al.
An Unconventional Antigen Translated by a Novel Internal Ribosome Entry Site Elicits Antitumor Humoral Immune Reactions
J. Immunol.,
October 1, 2006;
177(7):
4907 - 4916.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Prchal
Erythropoietin-independent erythroid colonies: is the molecular basis clarified?
Blood,
September 1, 2006;
108(5):
1431 - 1432.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Prchal
Does JAK2 1849G>T initiate polycythemia vera?
Blood,
July 1, 2006;
108(1):
8 - 9.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bellanne-Chantelot, I. Chaumarel, M. Labopin, F. Bellanger, V. Barbu, C. De Toma, F. Delhommeau, N. Casadevall, W. Vainchenker, G. Thomas, et al.
Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders
Blood,
July 1, 2006;
108(1):
346 - 352.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Pardanani, T. Lasho, R. McClure, M. Lacy, and A. Tefferi
Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders.
Blood,
June 1, 2006;
107(11):
4572 - 4573.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Goerttler, C. Steimle, E. Marz, P. L. Johansson, B. Andreasson, M. Griesshammer, H. Gisslinger, H. Heimpel, and H. L. Pahl
The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients
Blood,
October 15, 2005;
106(8):
2862 - 2864.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kralovics, F. Passamonti, A. S. Buser, S.-S. Teo, R. Tiedt, J. R. Passweg, A. Tichelli, M. Cazzola, and R. C. Skoda
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
N. Engl. J. Med.,
April 28, 2005;
352(17):
1779 - 1790.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Ferraris, R. Mangerini, N. Pujic, O. Racchi, D. Rapezzi, A. Gallamini, S. Casciaro, and G. F. Gaetani
High telomerase activity in granulocytes from clonal polycythemia vera and essential thrombocythemia
Blood,
March 1, 2005;
105(5):
2138 - 2140.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Vainchenker and S. N. Constantinescu
A Unique Activating Mutation in JAK2 (V617F) Is at the Origin of Polycythemia Vera and Allows a New Classification of Myeloproliferative Diseases
Hematology,
January 1, 2005;
2005(1):
195 - 200.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
